Table 1.
The clinical characteristics of 16 high-grade serous carcinoma patients
| ID | Group | Age (year) | Stage | Residual lesion | Sreum CA125(IU/ml) | PFS (months) | OS (months) |
|---|---|---|---|---|---|---|---|
| Pt01 | R | 69 | IIIC | R1 | 1808 | 0 | 16 |
| Pt02 | R | 60 | IIIC | R0 | 946 | 4 | S* |
| Pt03 | R | 49 | IIIC | R1 | 368 | 4 | 15 |
| Pt04 | R | 69 | IIIC | R1 | 1396 | 3 | S* |
| Pt05 | R | 62 | IIIA | R1 | 984 | 5 | 28 |
| Pt06 | R | 54 | IIIC | R0 | 348 | 0 | 28 |
| Pt07 | R | 57 | IIIC | R0 | 1758 | 4 | 52 |
| Pt08 | S | 41 | IIIC | R1 | 328 | 13 | S* |
| Pt09 | S | 65 | IIIC | R1 | 2023 | 19 | 30 |
| Pt10 | S | 53 | IIIC | R1 | 1397 | 13 | 42 |
| Pt11 | S | 63 | IVA | R1 | 30 | 16 | 32 |
| Pt12 | S | 42 | IIIC | R1 | 216 | 13 | S* |
| Pt13 | S | 66 | IIIB | R1 | 3092 | 17 | S* |
| Pt14 | S | 53 | IIIC | R0 | 473 | 22 | S* |
| Pt15 | S | 36 | IVA | R1 | 2395 | 17 | S* |
| Pt16 | S | 47 | IIIC | R1 | 4322 | 14 | 36 |
R Platinum resistance group, S Platinum sensitive group, R0 No macroscopic residual disease, R1 Residuals 1-10 mm, S* survival